typical bpc 157 dosage BPC-157 Dosing (Common Protocols), πΉ Oral / Subcutaneous, β’ 500 mcg daily, β’ Duration: 6 weeks, πΉ Intramuscular / Peritendinous, β’ 1 mg daily, β’ Duration: 6 weeks, β οΈ Note:, Not approved by FDA or BPC-157 Peptide: Benefits, Dosage &
Description
Results The current study shows that these derivatives have the potential to improve memory in mice by inhibiting scopolamine-induced acetylcholinesterase activity, oxidative and nitrosative stress, and improving locomotor activity and muscle grip strength in the rota rod test

198 , 553.e551-556 (2008)
Jour Clin Med Res

You need JavaScript enabled to view it
Oh, Shal, if you are in the UK, 180 is far too low

PhaseOne supplies BPC-157 for research purposes Australia-wide with independent HPLC testing on every batch
